CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Ambrisentandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725361
NCT00725361N/ACompleted
CompareCT.gov

A Pilot Study to Evaluate the Efficacy of Ambrisentan in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis.

Stanford University·interventional·Posted Jul 30, 2008·Updated Mar 31, 2017

In Brief

A clinical study evaluating Ambrisentan for n Ulcer and Scleroderma, Systemic. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Conditionsn Ulcer, Scleroderma, Systemic
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago

Interventions

Ambrisentandrug